Not Found
Webinar

ATA Product Theater: TEPEZZA® (teprotumumab-trbw): The First and Only FDA-Approved Treatment for Thyroid Eye Disease (TED)


Duration:
1 Hour

Dates
Please Note: Programs with a ☾ insignia begin after 5pm or air on the weekend.

Price


Tag: Live


Description

American Thyroid Association (ATA) Product Theater:

TEPEZZA® (teprotumumab-trbw): The First and Only FDA-Approved Treatment for Thyroid Eye Disease (TED)
Presented by Horizon Therapeutics

 

September 22, 2020 
7:00 pm – 8:00 pm ET / 6:00 pm – 7:00 pm CT / 4:00 pm – 5:00 pm PT

Presented by:

Gary J. Lelli, Jr, MD
Ophthalmic Plastic, Reconstructive and Orbital Surgery
New York-Presbyterian Hospital
Weill Cornell Department of Ophthalmology
New York, NY

 

Terry J. Smith, MD
Frederick G.L. Huetwell Professor
Ophthalmology and Visual Sciences
Professor of Internal Medicine
University of Michigan Medical School
Ann Arbor, MI

Program Description:

This program will focus on TEPEZZA, the first and only FDA-approved treatment for TED, a serious, vision-threatening autoimmune disease with debilitating consequences for patients. Come learn about the novel mechanism of action and how TEPEZZA is shifting the paradigm of TED management. The program will also highlight the clinical efficacy and safety of TEPEZZA and practical applications of treatment. 

This presentation is intended for US healthcare professionals.


Learning Objectives

  • Provide an overview of Thyroid Eye Disease (TED) and review the pathophysiology  
  • Describe the mechanism of action of TEPEZZA
  • Present clinical data highlighting the efficacy and safety of TEPEZZA for TED
  • Describe how to administer, monitor, and manage potential adverse reactions for TEPEZZA 

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA.  Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate. 

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA. 

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia.  Hyperglycemic events should be managed with medications for glycemic control, if necessary.  Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA.  Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA. 

Adverse Reactions
The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin. 

For additional information on TEPEZZA, please see Full Prescribing Information at TEPEZZAhcp.com.


NOTE: The ATA has external financial and business relationships with partners in the pharmaceutical and medical industry, which are important for its mission. ATA does not endorse any company, program or service provided by our partners. This information is provided for informational purposes and does not necessarily reflect the viewpoints of the ATA. 

To learn more about upcoming ATA programs or to become an ATA Partner, visit the ATA website at www.thyroid.org

 

Credits



Faculty

Gary J. Lelli, Jr.'s Profile

Gary J. Lelli, Jr. Related seminars and products: 1


Ophthalmic Plastic, Reconstructive and Orbital Surgery
New York-Presbyterian Hospital
Weill Cornell Department of Ophthalmology
New York, NY

Gary J. Lelli is Vice Chair of Ophthalmology, Director of Ophthalmic Plastic, Reconstructive, and Orbital Surgery, and Associate Professor of Ophthalmology at Weill Cornell Medical Center/New York-Presbyterian Hospital in New York, NY. Dr. Lelli received his doctor of medicine degree from the Mount Sinai School of Medicine in New York, NY; completed his internship at Saint Vincent’s Catholic Medical Center in New York, NY; and completed his residency in ophthalmology at the University of Michigan Kellogg Eye Center in Ann Arbor, MI. Dr. Lelli completed his American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) at the combined New York City ASOPRS program, where he now serves as the fellowship director. Dr. Lelli is a member of numerous professional societies, including the American Academy of Ophthalmology, the Associational for Research in Vision and Ophthalmology, and the American Society of Ophthalmic Plastic & Reconstructive Surgery. Additionally, Dr. Lelli is a reviewer for several journals, including the American Journal of Ophthalmology, Ophthalmic Plastic and Reconstructive Surgery, and the British Journal of Ophthalmology, and has written numerous papers and textbook chapters. In addition to presenting at national and international meetings, Dr. Lelli actively participates in global mission work, and to this end, has taught and performed surgeries in East Africa. Dr. Lelli’s clinical interests include eyelid, orbital, and lacrimal system disorders.

 

 

 


Terry J. Smith's Profile

Terry J. Smith Related seminars and products: 1

Kellogg Eye Center


Frederick G.L. Huetwell Professor
Ophthalmology and Visual Sciences
Professor of Internal Medicine
University of Michigan Medical School
Ann Arbor, MI

Terry J. Smith is the Frederick G.L. Huetwell Professor of Ophthalmology and Visual Sciences and Professor of Internal Medicine at the University of Michigan Kellogg Eye Center in Ann Arbor, MI. Dr. Smith received his doctor of medicine degree at the University of Missouri School of Medicine in Columbia, MO; completed his internship at the Abraham Lincoln School of Medicine in Chicago, IL; and completed his residency at Sinai Hospital in Baltimore, MD. He completed fellowships in biophysics, molecular biochemistry, and clinical endocrinology from the University of California in San Francisco, CA, Columbia University in New York, NY, and University of Chicago Pritzker School of Medicine in Chicago, IL, respectively. Dr. Smith is a member of numerous professional societies, including the Endocrine Society and the Orbital Society. In addition to authoring numerous articles and book chapters, Dr. Smith also serves as a reviewer for numerous scientific journals. He has been awarded 5 patents for research discoveries and is the Chief Scientific Officer for the National Graves’ Foundation. Dr. Smith’s clinical interests include Graves’ disease, thyroid-associated ophthalmology, and metabolic diseases.



About Horizon

                      
Horizon Therapeutics
 
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. 
 
To learn more about TEPEZZA, visit http://tepezzahcp.com

 

Connect with a Horizon Therapeutics Representative: 
1-855-380-0472
 
Horizon Patient Services™ 
 
Phone: 1-833-5-TEPEZZA 
 
Medical Information:
 
Phone: 1‐866‐479‐6742 

 

 

About ATA

American Thyroid Association

 

Who We Are

The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community. ATA® is a global professional medical society with more than 1,700 members from 70 countries around the world.  Our vision is a world in which there is “Optimal Thyroid Health for all”. Our members and staff are dedicated to making the world a better place for patients suffering with thyroid disease and thyroid cancer.  The philanthropic support of our members, the public, and grateful patients helps ATA to support research that advances clinical care and improves patient outcomes.  We hold ourselves to the highest standards of nonprofit and charitable organizations. 


Our Values

Our core values set a foundation for our organizational culture and are essential elements of our strategic foundation.  As an organization we believe in:

  • Scientific inquiry
  • Clinical excellence
  • Patient advocacy
  • Education
  • Public service
  • Diversity, equity and inclusion
  • Ethical conduct,
  • Worldwide collaboration and collegiality

What We Do

ATA provides researchers and clinicians with networking opportunities and resources that will help them grow their careers and stay current on leading-edge research and advances in clinical care. Additionally, ATA is committed to providing patients and their families with reliable information and tools to help them learn more about and manage their thyroid disease and thyroid cancer.

Highlights of our programs include:

  • Publishing highly regarded professional journalsThyroid®Clinical Thyroidology®, and VideoEndocrinology™;
  • Disseminating Clinical Thyroidology®for the Public(distributed free of charge to over 14,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish.
  • Hosting the “Find a specialist” patient resource connecting clinical thyroidologists to patients in North America and around the world.
  • Publishing Clinical Management Guidelines for thyroid diseases and thyroid cancer.
  • Establishing a centralized search engine of clinical trials related to thyroid disease.
  • Coordinating “Friends of the ATA” – a resource for patients to receive monthly updates by email on the latest thyroid research and answers to frequently asked questions.
  • Funding thyroid research grants through partnerships with Bite Me Cancer, THYCA, and the New Hampshire Charitable Foundation.
  • Organizing scientific educational symposia on thyroid research and clinical treatment to improve the lives of patients and the understanding of thyroid function.
  • Supporting trainees through programs like the Chester Ridgway Conference
  • Collaborative efforts with endocrine, surgery and nuclear medicine societies

Learn More and Join the ATA

To Join the ATA or learn more about of our services, visit www.thyroid.org or contact us at thyroid@thyroid.org.

 

Disclosure

The American Thyroid Association provides financial disclosure information for all faculty participating in ATA educational initiatives for the benefit of our learners.
 
Faculty Disclosures 
 
Gary J. Lelli, Jr, MD and Terry J. Smith, MD intend to reference on-label/approved uses of products or devices and have reported the following relevant financial relationship(s): 
 
Gary J. Lelli, Jr, MD is a consultant for Horizon Therapeutics.
 
Terry J. Smith, MD  reports grants from NIH, U.S. Patents, consulting fees from Horizon Therapeutics and Immunovant, grants from NIH and U.S. Patents outside the submitted work;  Issued patents (Dr. Smith and UCLA/LABIOMED): US patent 6936426, US patent 7998681, US patent 8153121, US patent 8178304.

Please wait ...

Back to Top